EndoZyme® - Enhanced Recombinant Factor C (rFC) Endotoxin A

JAVASCRIPT DISABLED - This site works best with JavaScript enabled.

Next article »
FDA Clearance for Lu...

21st January 2013 Content supplied by: Hyglos GMBH

EndoZyme® - Enhanced Recombinant Factor C (rFC) Endotoxin Assay

Hyglos is today pleased to announce the commercial launch of EndoZyme®, a homogeneous fluorescence microplate assay using recombinant Factor C derived from horseshoe crab, for measuring endotoxin(Lipopolysaccharides, LPS) in pharmaceuticals, biologics and medical equipment.

Taking up on the pioneering work published by the Japanese scientists around Prof. Sadaaki Iwanaga, the test developers at Hyglos have been able to finalize an improved recombinant Factor C (rFC) assay.

Recombinant factor C, which is the essential part of EndoZyme®, is the endotoxin-specific principal receptor in the LAL enzyme cascade. In the assay recombinant Factor C is activated by any endotoxin present in the sample, recombinant Factor C enzymatically cleaves a synthetic substrate resulting in a fluorescence signal.

EndoZyme® at a glance:

Improved sensitivity and measurement range 0.005 EU/ml to 50 EU/ml
Excellent correlation to LAL
No false-positive glucan reaction due to endotoxin-specific recombinant technology
Reliability and lot-to-lot consistency
No animal material, therefore saving the diminishing horseshoe crab population

Lipopolysaccharides (LPS), or endotoxins, are biologically active components (toxins) of the outer cell membrane of all Gram-negative bacteria. Presence of endotoxins in the blood stream causes a triggering of the signaling cascade and may lead to endotoxic shock. In production of parental drugs, infusions and certain medical devices it is mandatory to control endotoxin.